基于下一代腺病毒载体的严重急性呼吸综合征冠状病毒2疫苗

Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.

作者信息

Murala Muralimanohara S T, Gairola Vivek, Sayedahmed Ekramy E, Mittal Suresh K

机构信息

Department of Comparative Pathobiology, Purdue Institute of Inflammation, Immunology and Infectious Disease, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907-2027, USA.

出版信息

Vaccines (Basel). 2025 Apr 14;13(4):406. doi: 10.3390/vaccines13040406.

DOI:10.3390/vaccines13040406

PMID:40333307

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12031563/

Abstract

This review systematically revises adenovirus (Ad) biology, vector structure, immune responses, and currently available Ad vector COVID-19 vaccines. It analyzes the challenges associated with the Ad vector-based vaccines, including preexisting vector immunity and other side effects. Moreover, this review explores novel and innovative strategies to overcome these constraints for developing next-generation vaccines for broad protection to cover emerging SARS-CoV-2 variants. The future refinement of Ad vaccine platforms will be pivotal in achieving durable immunity against emerging variants for global preparedness.

摘要

本综述系统地修订了腺病毒（Ad）生物学、载体结构、免疫反应以及目前可用的腺病毒载体COVID-19疫苗。它分析了与腺病毒载体疫苗相关的挑战，包括预先存在的载体免疫和其他副作用。此外，本综述探讨了新颖和创新的策略，以克服这些限制，开发下一代疫苗，实现广泛保护，以应对新出现的SARS-CoV-2变体。腺病毒疫苗平台的未来改进对于实现针对新出现变体的持久免疫力以实现全球防备至关重要。